Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.93 USD | +2.51% | -4.84% | +76.25% |
Mar. 26 | Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating | MT |
Mar. 18 | Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding | CI |
Financials (USD)
Sales 2024 * | 6.82M | Sales 2025 * | 5.17M | Capitalization | 1.37B |
---|---|---|---|---|---|
Net income 2024 * | -169M | Net income 2025 * | -167M | EV / Sales 2024 * | 108 x |
Net cash position 2024 * | 638M | Net cash position 2025 * | 333M | EV / Sales 2025 * | 201 x |
P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
-12.8
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.45% |
Latest transcript on Spyre Therapeutics, Inc.
1 day | +2.51% | ||
1 week | -4.84% | ||
Current month | +38.23% | ||
1 month | +45.33% | ||
3 months | +85.02% | ||
6 months | +230.98% | ||
Current year | +76.25% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 38 | 23-06-21 |
Russell Cox
CHM | Chairman | 60 | 15-05-31 |
Jeffrey Albers
BRD | Director/Board Member | 51 | Nov. 26 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 37.93 | +2.51% | 951,529 |
24-03-27 | 37 | -1.62% | 573,502 |
24-03-26 | 37.61 | -2.26% | 327,872 |
24-03-25 | 38.48 | -6.60% | 456,371 |
24-03-22 | 41.2 | +3.36% | 302,065 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.25% | 1.37B | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |